Systemic manipulation of the RAS, especially by interfering with the signaling of angiotensin II (AngII) at the angiotensin II receptor type 1 (AT1R), is now a mainstay of treatment in cardiovascular disease. The gene discussed is AGT; the disease is cardiovascular disorder.